Adult patients suffering from episodic or chronic migraines, you can ease the disease with a new drug, approved in the work the results of the recently completed study. We are talking about the antibody to the peptide encoded by the genome of calcitonin (or calcitonin-related peptide). International nonproprietary name of the drug — calcaneum (galcanezumab). The tool was developed by the pharmaceutical company Eli Lilly and Company.
To date, successfully completed clinical phase III trials. The results of the work presented in the papers and poster sessions Annual scientific meeting (Annual Scientific Meeting) of the American headache society (American Headache Society).
The drug was studied in two clinical trials, EVOLVE 1, and EVOLVE 2, with virtually identical design. In total, the trials involved more than 1,700 volunteers with episodic migraine attacks. Study participants who took 120 or 240 mg galantuomo, demonstrated a significant decrease in the number of days with seizures compared with those who received placebo.
The secondary endpoint of the trials, the authors of the research chose reduction in the number of days with migraine attacks at 50, 70 or 100%. In the experimental groups, it was also achieved significantly more frequently than in the control.
In the work of REGAIN, which involved patients with chronic migraine were achieved similar results.
“We are very pleased with the results. Data from all three works are in good agreement among themselves and also with the results of other studies of a class of drugs,” says Dr. Eric Pearlman (Pearlman Eric), medical Director of the headache of the U.S. representative office of Eli Lilly. Dr. Perlman also said that the Management on sanitary inspection behind quality of foodstuff and medicines (Food and Drug Administration) data will be presented in the second half of 2017.
Also during the meeting of the American headache society was presented the positive results of clinical trials of III phase of HALO-HALO and CM-EM . In the course of these works studied another drug of the same pharmacological group, Premantura (fremanezumab), development, Teva Pharmaceuticals Industries, Ltd. means to deal with chronic and episodic migraine attacks.
Another drug, eptanissa (eptinezumab) with the same readings successfully passed clinical trials phase II.
“This is the first class of drugs developed specifically for migraine treatment. All other funds used to combat migraine, was originally created to treat other diseases, says Dr. Pearlman. — I think that’s why these drugs has caused great interest among the participants. But it also indicates unmet to date the need for treatment of migraine in patients with this diagnosis.”